News & Publications

Xilis Presents Data at ESMO 2021 Demonstrating Capabilities of MicroOrganoSphere™ Technology for Cancer Drug Screening

Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology

Press Release: Xilis believes cultivating micro-tumors may hold the key to more effective cancer treatments.

Xilis closed seed funding round led by Felicis Ventures and followed by Pear VC, 8VC, and Liquid 2 Ventures.

Xilis closed pre-seed funding round led by Pear VC.